April 2017- Volume 13, Issue 4

In this Issue

Feature

Show Preview: Immunology 2017--In the interests of immunology

Show Preview: Immunology 2017--In the interests of immunology

The largest annual gathering of immunologists worldwide will hold its annual meeting in Washington, D.C.

Discovery

Allergens or irritants?

Allergens or irritants?

SenzaGen and AstraZeneca collaborate on respiratory technology development

Santen Inc. tags twoXAR for new deal

Santen Inc. tags twoXAR for new deal

Strategic research collaboration will explore new glaucoma treatments

A pair of GPCR deals for Q1

A pair of GPCR deals for Q1

Heptares inks agreements with Daiichi Sankyo and University of Cambridge centered on GPCRs

A different tack for Alzheimer’s research

A different tack for Alzheimer’s research

‘Jumping genes’ may set stage for brain cell death in Alzheimer’s disease

Preclinical

Making preclinical science stronger

Making preclinical science stronger

Global Biological Standards Institute’s release of reproducibility report adds rigor to research

JAX vs. TNBC

JAX vs. TNBC

Defense Department awards Jackson Laboratory major grants to target triple-negative breast cancer

Valerion reports preclinical potential for Pompe treatment

Valerion reports preclinical potential for Pompe treatment

VAL-1221 could offer more widespread clearance of glycogen than current standard ERT

Attune announces ATN-249 preclinical data

Attune announces ATN-249 preclinical data

Presentation for the oral plasma kallikrein inhibitor for treatment of hereditary angioedema took place at AAAAI 2017

Research & Development

IU applies cell coloring technology to battle superbugs

IU applies cell coloring technology to battle superbugs

Study sheds new light on the biochemical mechanisms behind cellular division in bacteria

Mar matters

Mar matters

Mount Sinai team demonstrates how rare mutations can be lost in stem cell disease modeling of psychosis

A new way to study SVs

A new way to study SVs

Posters at AGBT demonstrate clinical significance of next-generation mapping

‘Eureka moment’

‘Eureka moment’

City of Hope researchers identify possible cause of type 1 diabetes

Business & Government Policy

Just say yes to druggable targets

Just say yes to druggable targets

New biotech Vividion Therapeutics launches with $50-million Series A financing

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Targets acquired

Targets acquired

A look at a few recent merger and acquisition deals in the pharma world

Contract Services

Strengthening standards for clinical research

Strengthening standards for clinical research

IAOCR seeks to tighten competency requirements, in part with an eye toward life-sciences health of UK post-Brexit

Double the drug discovery options

Double the drug discovery options

Assay.Works and Metrion announce collaboration for expanded service offerings

Genesis Biotechnology acquires PharmOptima

Genesis Biotechnology acquires PharmOptima

Clients will be able to work with one provider for early discovery through preclinical candidate identification

Diagnostics

Graphene method may lead to low-cost diagnostics

Graphene method may lead to low-cost diagnostics

New approach could enable pinpoint diagnostics on individual blood cells

Positive news for ovarian cancer patients

Positive news for ovarian cancer patients

Peregrine shares data supporting a new kind of cancer diagnostic

A clinic-focused agreement

A clinic-focused agreement

NeoGenomics and Definiens link up for clinical trials, clinical testing

Clinical Trials

Blueprint advances on multiple cancer fronts

Blueprint advances on multiple cancer fronts

Encouraging results seen for both BLU-554 and BLU-285, while BLU-667 gains IND approval

Certara launches Simcyp Access

Certara launches Simcyp Access

New licensing approach allows smaller organizations easier access to PBPK modeling and simulation platform

REVEAL-ing the truth about CETP inhibitors?

REVEAL-ing the truth about CETP inhibitors?

International study examines adding anacetrapib to effective LDL-lowering treatment with atorvastatin

Silver lining for selinexor

Silver lining for selinexor

Karyopharm declares Phase 2 SOPRA study of selinexor a failure, but outlook remains bullish

Special Reports

Editor's Focus

That crisp new CRISPR feeling

That crisp new CRISPR feeling

We peek at some relatively recent CRISPR news to whet your appetite as we get ready to devote a special section to the topic in our May 2017 issue

Commentary

Convergence: Where art thou?

Convergence: Where art thou?

There's a lot of talk about the need for convergence in healthcare and life-sciences research, but first we have to cut through a ton of divergent tendencies

Guest Commentary: Using EHR data in research--Pragmatic trials are just the beginning

Guest Commentary: Using EHR data in research--Pragmatic trials are just the beginning

Pragmatic trials could usher in a new era for discovery, but unless we can consistently apply what we know to patients, such discovery will be for naught; as such, we need to tap into the efficiencies of electronic health records and learn to apply these data and IT systems across the entire spectrum of research activities

Q&A

Q&A: How electronic data capture is changing clinical trials

Q&A: How electronic data capture is changing clinical trials

Adam Butler of Bracket touches on the growing adoption of eCOA and RTSM in the clinic
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN May 2022 Issue 5 Volume 18 Front Cover

Latest Issue  

• Volume 18 • Issue 5 • May 2022

May 2022

May 2022 Issue